BI 34021

Drug Profile

BI 34021

Alternative Names: BI 34021 FU2; BI34021

Latest Information Update: 16 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 01 Oct 2014 Discontinued - Phase-I for Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)
  • 23 Jun 2008 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02259842)
  • 28 Mar 2008 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top